Selective Estrogen Receptor Modulators
"Selective Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)
| Descriptor ID |
D020845
|
| MeSH Number(s) |
D06.347.360.827 D27.505.696.399.450.360.827
|
| Concept/Terms |
Selective Estrogen Receptor Modulators- Selective Estrogen Receptor Modulators
- SERMs
- Estrogen Receptor Modulators, Selective
- Selective Estrogen Receptor Modulator
- SERM
- Estrogen Receptor Modulator, Selective
|
Below are MeSH descriptors whose meaning is more general than "Selective Estrogen Receptor Modulators".
Below are MeSH descriptors whose meaning is more specific than "Selective Estrogen Receptor Modulators".
This graph shows the total number of publications written about "Selective Estrogen Receptor Modulators" by people in this website by year, and whether "Selective Estrogen Receptor Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Selective Estrogen Receptor Modulators" by people in Profiles.
-
Persistent Metabolic Effects of Tamoxifen: Considerations for an Experimental Tool and Clinical Breast Cancer Treatment. Endocrinology. 2021 09 01; 162(9).
-
Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study. Patient Educ Couns. 2017 Dec; 100(12):2346-2354.
-
Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev Res (Phila). 2014 Mar; 7(3):300-9.
-
Synthesis and biological evaluation of 2,3,4-triarylbenzopyran derivatives as SERM and therapeutic agent for breast cancer. Bioorg Med Chem. 2009 Oct 01; 17(19):6832-40.
-
27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007 Oct; 13(10):1185-92.
-
The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol. 2005 Aug 15; 175(4):2666-75.
-
Estrogens, progestins, selective estrogen receptor modulators, and the arterial tree. Am J Obstet Gynecol. 2001 Apr; 184(5):1031-9.